Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$0.87 USD
+0.04 (5.31%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $0.89 +0.02 (1.83%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OVID 0.87 +0.04(5.31%)
Will OVID be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OVID
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates
Other News for OVID
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
Ovid Therapeutics Announces Workforce Reduction to Extend Runway
Catalyst Watch: Tesla deliveries, Constellation Brands earnings, and the June Jobs Report
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today